Victory Capital Management Inc. Has $23.37 Million Stock Holdings in Insulet Co. (NASDAQ:PODD)

Victory Capital Management Inc. lessened its position in Insulet Co. (NASDAQ:PODD – Get Rating) by 42.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 80,903 shares of the medical instruments supplier’s stock after selling 59,240 shares during the period. Victory Capital Management Inc. owned about 0.12% of Insulet worth $23,373,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Allworth Financial LP lifted its position in Insulet by 166.7% during the 4th quarter. Allworth Financial LP now owns 88 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 55 shares in the last quarter. Huntington National Bank lifted its position in Insulet by 448.4% during the 3rd quarter. Huntington National Bank now owns 170 shares of the medical instruments supplier’s stock worth $39,000 after buying an additional 139 shares in the last quarter. Bessemer Group Inc. acquired a new position in Insulet during the 3rd quarter worth about $53,000. Spartan Planning & Wealth Management acquired a new position in Insulet during the 4th quarter worth about $157,000. Finally, Profund Advisors LLC acquired a new position in Insulet during the 4th quarter worth about $205,000.

Insulet Trading Down 0.6 %

NASDAQ PODD opened at $301.03 on Monday. The company has a market cap of $20.98 billion, a PE ratio of 257.29 and a beta of 0.80. The company has a current ratio of 3.47, a quick ratio of 2.46 and a debt-to-equity ratio of 2.72. Insulet Co. has a 12 month low of $191.77 and a 12 month high of $335.91. The stock has a 50 day moving average of $316.99 and a 200-day moving average of $302.25.

Insulet (NASDAQ:PODD – Get Rating) last posted its quarterly earnings results on Thursday, May 4th. The medical instruments supplier reported $0.23 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.14. Insulet had a return on equity of 17.29% and a net margin of 0.04%. The business had revenue of $358.10 million for the quarter, compared to analysts’ expectations of $330.21 million. During the same quarter in the prior year, the business earned $0.40 EPS. The firm’s revenue for the quarter was up 21.2% on a year-over-year basis. On average, equities research analysts anticipate that Insulet Co. will post 1.34 EPS for the current fiscal year.

Insider Activity at Insulet

In related news, CFO Wayde D. Mcmillan sold 1,255 shares of the stock in a transaction on Monday, April 3rd. The stock was sold at an average price of $318.31, for a total value of $399,479.05. Following the sale, the chief financial officer now owns 22,865 shares in the company, valued at approximately $7,278,158.15. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Insulet news, insider Charles Alpuche sold 4,000 shares of the stock in a transaction on Thursday, March 9th. The stock was sold at an average price of $290.90, for a total transaction of $1,163,600.00. Following the transaction, the insider now owns 45,584 shares in the company, valued at approximately $13,260,385.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Wayde D. Mcmillan sold 1,255 shares of the stock in a transaction on Monday, April 3rd. The stock was sold at an average price of $318.31, for a total value of $399,479.05. Following the transaction, the chief financial officer now owns 22,865 shares in the company, valued at approximately $7,278,158.15. The disclosure for this sale can be found here. In the last quarter, insiders have sold 32,656 shares of company stock worth $9,819,174. Company insiders own 0.90% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on PODD shares. Robert W. Baird upped their price target on shares of Insulet from $350.00 to $370.00 in a research report on Friday, May 5th. Morgan Stanley boosted their price objective on Insulet from $320.00 to $325.00 and gave the stock an “equal weight” rating in a report on Friday, February 24th. UBS Group boosted their price objective on Insulet from $328.00 to $360.00 in a report on Friday, May 5th. Barclays boosted their price objective on Insulet from $292.00 to $329.00 in a report on Monday, May 8th. Finally, BTIG Research upped their price target on Insulet from $340.00 to $350.00 and gave the company a “buy” rating in a research note on Monday, April 17th. Eight equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $330.00.

Insulet Profile

(Get Rating)

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals.